Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

APRIL 11, 2023

Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. This gene-independent treatment approach has significant advantages in RP, which has multiple genetic causes.

Small Molecule 130

Small Molecule Drugs Treatment Regulations 130

Drug Discovery World

JANUARY 23, 2023

Over the three days of Advanced Therapies Week (ATW) 2023 in Miami, Florida, US, from 18 to 20 January, DDW’s Megan Thomas heard from attendees about what they were most looking forward to learning from the event, as well as why they think the potential of cell and gene therapies outweighs the obstacles that must be overcome to achieve it.

Therapies 246

Therapies Small Molecule Production Treatment 246

Drug Discovery World

MARCH 15, 2023

The treatment was also well tolerated, with no serious adverse events (AEs) reported in the AP30663 groups. Anders Gaarsdal Holst, Chief Executive Officer of Acesion, commented: “This clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation.

Trials 130

Trials Small Molecule Clinical Trials Treatment 130

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. In addition, we have advanced zavegepant, our intra-nasal CGRP receptor antagonist, successfully through its first pivotal trial, also for the acute treatment of migraine. TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

NOVEMBER 10, 2023

Topline results from a Phase I/II clinical trial have shown that Kiora’s light-restoring small molecule KIO-301 has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP). KIO-301 was safe and well tolerated with no ocular and non-ocular serious adverse events, nor any signs of retinal inflammation.

Clinical Trials 130

Clinical Trials Small Molecule Trials Clinical Development 130

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) International Molecular Biology 40

Drug Discovery World

APRIL 6, 2023

Science ↔ Survivor Program As mentioned previously, AACR has a Scientist↔Survivor Program. Its purpose is to build enduring partnerships between the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

JUNE 5, 2023

DDW’s Megan Thomas comments on the event. New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk.

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Discovery World

APRIL 8, 2024

In December 2023, Pfizer announced that it had chosen to donate the rights of its royalties from the sale of Bavencio (avelumab) in the United States to the AACR, as an acknowledgment of the AACR’s dedication to sustained innovation in cancer research and treatment.

DNA 130

DNA Small Molecule Science Treatment 130

Drug Discovery World

APRIL 27, 2023

Research spotlight : In February 2023, Duke University co-investigators took a groundbreaking step in the treatment of geographic atrophy (GA), an advanced form of dry macular degeneration through the FDA approval of pegcetacoplan, the first ever FDA-approved treatment for GA.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Discovery World

JANUARY 4, 2024

ANX1502 is a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway activation in association with C1q. Across all doses evaluated, ANX1502 was generally well tolerated with mild to moderate treatment-emergent adverse events (TEAEs).

Small Molecule 130

Small Molecule Pharmacokinetics Clinical Development Disease 130

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. Here are eight anticipated ‘curtain raisers’ in advance of the event: 1.

Virus 130

Virus Clinical Trials Trials Therapies 130

The Pharma Data

JANUARY 13, 2021

Preliminary analyses showed no clinically meaningful differences in safety results between the dexpramipexole and placebo groups, with no serious adverse events and 96% of subjects completing the primary assessment phase. Background standard of care was inhaled corticosteroids in combination with a long-acting ?2 President and CEO of Knopp.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

MARCH 28, 2022

Tomorrow, Sanofi will host an Immunology Investor Event with key members of the leadership team providing updates on how the company is advancing its Immunology strategy, including the ambition to more than quadruple Immunology franchise sales by the end of the decade. A broad Phase 1 clinical program of small molecules and biologics.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Drug Discovery World

SEPTEMBER 9, 2024

Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60.

Treatment 147

Treatment Pharmacokinetics Small Molecule Trials 147

The Pharma Data

AUGUST 18, 2020

Johnson & Johnson statement on the launch of new CARE (Corona Accelerated R&D in Europe) consortium, Europe’s largest, multi-partner scientific research initiative dedicated to discovering and developing urgently needed treatment options for COVID-19. Small molecule discovery. Virus-neutralizing antibody discovery.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

Drug Discovery World

NOVEMBER 1, 2022

Additionally, no drug related serious adverse events have been observed. . Based on these findings, Aucentra have further amended the study protocol in light of the recent pharmacology findings to now include twice daily dosing of Auceliciclib for 28 days of each treatment cycle for monotherapy and combination dose escalation arms.

Drugs 130

Drugs Science Therapies Clinical Trials 130

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. (OTCQB: QBIO), announced today that the U.S. .

FDA 40

FDA Treatment Small Molecule Government 40

The Pharma Data

AUGUST 30, 2021

The study will allow assessment of any difference in efficacy that may persist at month 6 of treatment. A larger percentage of patients treated with abrocitinib 200mg experienced adverse events compared to dupilumab 300mg. There were no cases of malignancies or venous thromboembolism (VTE) events confirmed through adjudication.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

The Pharma Data

NOVEMBER 8, 2021

“HER-MES is the first study that directly compared the therapeutic effects of an antibody and a small molecule in migraine prevention,” said Uwe Reuter, M.D., “The positive outcomes strengthen the efficacy and safety profile of erenumab as a migraine prevention treatment for patients with migraine.”

Therapies 52

Therapies FDA Approval Small Molecule Treatment 52

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

Advarra

FEBRUARY 24, 2023

But what does “working” really mean when efficacy means something subjective, like quality of life, reduced psychiatric events, or less symptoms? Also known as a clinical event committee (CEC), EAC members evaluate a clinical event in the context of the protocol and the individual participant’s medical information.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

DECEMBER 13, 2020

Due to the COVID -19 pandemic, the event will be hosted virtually. Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.

Small Molecule 40

Small Molecule FDA DNA Clinical Trials 40

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics. SOURCE Mirati Therapeutics, Inc.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

MARCH 4, 2021

Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients. Lennox-Gastaut syndrome can be caused by a variety of underlying conditions, but in some cases no cause can be identified.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Licensing 52

Drug Discovery World

SEPTEMBER 26, 2024

The Drug Discovery in Scotland Forum showcased how Scotland is shaping drug discovery using approaches including traditional small molecules, therapeutic proteins, CRISPR/ RNAi and cell therapies, as well as how these are being used in 2D and 3D models.

Small Molecule 147

Small Molecule Drugs Therapies Disease 147

The Pharma Data

OCTOBER 6, 2021

The adverse event profile was generally consistent with other clinical safety data for COMIRNATY. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

OCTOBER 1, 2021

Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO ® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies.

Clinical Trials 52

Clinical Trials Small Molecule Trials Production 52

Drug Discovery World

JULY 11, 2023

These different fundamental approaches (rules-based versus pattern recognition) to building these systems provide multiple opportunities to interject them into disease diagnostics and treatments. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Science 100

Science Drugs FDA Engineering 100

The Pharma Data

DECEMBER 10, 2020

We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). About LX9211. Source link.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Elrig

JUNE 4, 2024

Zahra Jawad is the founder and CEO of Creasallis, a company focused on antibody remodeling to improve penetration and treatment of solid tumours. The focus used to be more on small molecules, but we’re now starting to see antibody and cell therapeutics. Have you attended ELRIG before?

Small Molecule 52

Small Molecule Science Drugs Research 52

The Pharma Data

OCTOBER 25, 2020

Roxadustat is approved for the treatment of anemia associated with CKD in Japan in dialysis dependent patients and in China in both dialysis dependent and non-dialysis dependent patients. In the study, the drug demonstrated statistically significant and clinically meaningful efficacy and a favorable adverse event and tolerability profile.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52